Misdiagnosis of Human Herpes Virus-8-Associated Kaposi's Sarcoma as Adverse Drug Eruptions

Tae Hyung Kim; Syeo Young Wee; Hyun Gyo Jeong; Hwan Jun Choi

doi:10.1055/s-0042-1748664

Archives of Plastic Surgery, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · Arch Plast Surg 2022; 49(03): 457-461
DOI: 10.1055/s-0042-1748664

Extremity/Lymphedema

Case Report

Misdiagnosis of Human Herpes Virus-8-Associated Kaposi's Sarcoma as Adverse Drug Eruptions

Tae Hyung Kim

¹Department of Plastic and Reconstructive Surgery, Soonchunhyang University Gumi Hospital, Soonchunhyang University College of Medicine, Gumi, Republic of Korea

,

Syeo Young Wee

¹Department of Plastic and Reconstructive Surgery, Soonchunhyang University Gumi Hospital, Soonchunhyang University College of Medicine, Gumi, Republic of Korea

,

Hyun Gyo Jeong

¹Department of Plastic and Reconstructive Surgery, Soonchunhyang University Gumi Hospital, Soonchunhyang University College of Medicine, Gumi, Republic of Korea

,

Hwan Jun Choi

²Department of Plastic and Reconstructive Surgery, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, Republic of Korea

› Institutsangaben

Abstract

Kaposi's sarcoma (KS) is a cancer that causes patches of abnormal tissue to grow under the skin. It also occurs in the immunosuppressive population. KS is currently believed to be caused by infection with human herpes virus-8 (HHV-8) in non-human immunodeficiency virus patient. A 79-year-old female visited the outpatient clinic presenting with increasing number and size of palpable masses on both upper and lower extremities. She was first diagnosed as drug-erupted dermatitis and stopped her medications, but the symptoms got worse. We did partial biopsy, and KS with HHV-8 was diagnosed histopathologically. She planned to undergo further evaluations and proper treatments. This rare case suggests the need to consider a classic type of KS in the differential diagnosis of specific dermatologic symptoms such as macular, nodular, and darkish patches of upper or lower extremities in elderly patients. It is believed that this case helps to strengthen awareness of this rare disease.

Keywords

extremities - non-AIDS-related Kaposi sarcoma - adverse drug reactions

Volltext

Referenzen

References
1 Nickoloff BJ, Foreman KE. Etiology and pathogenesis of Kaposi's sarcoma. In: Dummer R, Nestle FO, Burg G. eds. Cancers of the Skin. vol. 160, Berlin, Heidelberg: Springer; 2002: 331-342
2 Kamiyango W, Villiera J, Silverstein A, Peckham-Gregory E, Campbell LR, El-Mallawany NK. Navigating the heterogeneous landscape of pediatric Kaposi sarcoma. Cancer Metastasis Rev 2019; 38 (04) 749-758
3 Tappero JW, Conant MA, Wolfe SF, Berger TG. Kaposi's sarcoma. Epidemiology, pathogenesis, histology, clinical spectrum, staging criteria and therapy. J Am Acad Dermatol 1993; 28 (03) 371-395
4 Schwartz RA. Kaposi's sarcoma: an update. J Surg Oncol 2004; 87 (03) 146-151
5 Nayak S, Acharjya B. Adverse cutaneous drug reaction. Indian J Dermatol 2008; 53 (01) 2-8
6 Vangipuram R, Tyring SK. Epidemiology of Kaposi sarcoma: review and description of the nonepidemic variant. Int J Dermatol 2019; 58 (05) 538-542
7 Rescigno P, Di Trolio R, Buonerba C. et al. Non-AIDS-related Kaposi's sarcoma: a single-institution experience. World J Clin Oncol 2013; 4 (02) 52-57
8 Lanternier F, Lebbé C, Schartz N. et al. Kaposi's sarcoma in HIV-negative men having sex with men. AIDS 2008; 22 (10) 1163-1168
9 Krown SE, Lee JY, Lin L. et al. Interferon-a2b with protease inhibitor–based antiretroviral therapy in patients with AIDS-associated Kaposi sarcoma. J Acquir Immune Defic Syndr 2006; 41: 5
10 Oyucu Orhan S, Bilgehan Sahin A, Cubukcu E. et al. Efficacy of chemotherapeutics in classic and non-classic Kaposi sarcoma: a single-center retrospective real-world data. Bosn J Basic Med Sci 2021; 21 (06) 746-751
11 Reid E, Suneja G, Ambinder RF. et al; CGC. AIDS-related Kaposi sarcoma, version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2019; 17 (02) 171-189
12 Schneider JW, Dittmer DP. Diagnosis and treatment of Kaposi sarcoma. Am J Clin Dermatol 2017; 18 (04) 529-539
13 Krown SE, Moser CB, MacPhail P. et al; A5263/AMC066 protocol team. Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial. Lancet 2020; 395 (10231): 1195-1207
14 Tsao MN, Sinclair E, Assaad D. et al. Radiation therapy for the treatment of skin Kaposi sarcoma. Ann Palliat Med 2016; 5 (04) 298-302
15 Lebbe C, Garbe C, Stratigos AJ. et al; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organisation for Research and Treatment of Cancer (EORTC). Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC). Eur J Cancer 2019; 114: 117-127